vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $140.7M, roughly 1.2× Purple Innovation, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
ESPR vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $140.7M |
| Net Profit | — | $-3.2M |
| Gross Margin | — | 41.9% |
| Operating Margin | 50.6% | -1.6% |
| Net Margin | — | -2.3% |
| Revenue YoY | 143.7% | 9.1% |
| Net Profit YoY | — | 62.1% |
| EPS (diluted) | $0.32 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $140.7M | ||
| Q3 25 | $87.3M | $118.8M | ||
| Q2 25 | $82.4M | $105.1M | ||
| Q1 25 | $65.0M | $104.2M | ||
| Q4 24 | $69.1M | $129.0M | ||
| Q3 24 | $51.6M | $118.6M | ||
| Q2 24 | $73.8M | $120.3M | ||
| Q1 24 | $137.7M | $120.0M |
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $-31.3M | $-11.7M | ||
| Q2 25 | $-12.7M | $-17.3M | ||
| Q1 25 | $-40.5M | $-19.1M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | $-29.5M | $-39.2M | ||
| Q2 24 | $-61.9M | $27.0K | ||
| Q1 24 | $61.0M | $-50.2M |
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 34.8% |
| Q4 25 | 50.6% | -1.6% | ||
| Q3 25 | -11.4% | -10.2% | ||
| Q2 25 | 8.6% | -13.5% | ||
| Q1 25 | -34.0% | -13.9% | ||
| Q4 24 | -6.4% | -6.0% | ||
| Q3 24 | -31.0% | -39.5% | ||
| Q2 24 | 3.5% | -12.1% | ||
| Q1 24 | 52.5% | -19.3% |
| Q4 25 | — | -2.3% | ||
| Q3 25 | -35.9% | -9.9% | ||
| Q2 25 | -15.4% | -16.5% | ||
| Q1 25 | -62.2% | -18.4% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -57.2% | -33.1% | ||
| Q2 24 | -83.9% | 0.0% | ||
| Q1 24 | 44.3% | -41.8% |
| Q4 25 | $0.32 | $0.03 | ||
| Q3 25 | $-0.16 | $0.11 | ||
| Q2 25 | $-0.06 | $0.16 | ||
| Q1 25 | $-0.21 | $0.18 | ||
| Q4 24 | $-0.14 | $0.08 | ||
| Q3 24 | $-0.15 | $0.36 | ||
| Q2 24 | $-0.33 | $0.00 | ||
| Q1 24 | $0.34 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $24.3M |
| Total DebtLower is stronger | — | $126.7M |
| Stockholders' EquityBook value | $-302.0M | $-29.7M |
| Total Assets | $465.9M | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $24.3M | ||
| Q3 25 | $92.4M | $32.4M | ||
| Q2 25 | $86.1M | $34.2M | ||
| Q1 25 | $114.6M | $21.6M | ||
| Q4 24 | $144.8M | $29.0M | ||
| Q3 24 | $144.7M | $23.4M | ||
| Q2 24 | $189.3M | $23.4M | ||
| Q1 24 | $226.6M | $34.5M |
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $-29.7M | ||
| Q3 25 | $-451.4M | $-26.9M | ||
| Q2 25 | $-433.5M | $-15.6M | ||
| Q1 25 | $-426.2M | $1.3M | ||
| Q4 24 | $-388.7M | $20.2M | ||
| Q3 24 | $-370.2M | $28.0M | ||
| Q2 24 | $-344.2M | $66.4M | ||
| Q1 24 | $-294.3M | $65.5M |
| Q4 25 | $465.9M | $296.3M | ||
| Q3 25 | $364.0M | $302.1M | ||
| Q2 25 | $347.1M | $303.8M | ||
| Q1 25 | $324.0M | $293.8M | ||
| Q4 24 | $343.8M | $307.8M | ||
| Q3 24 | $314.1M | $309.3M | ||
| Q2 24 | $352.3M | $362.1M | ||
| Q1 24 | $373.1M | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-5.8M |
| Free Cash FlowOCF − Capex | — | $-7.8M |
| FCF MarginFCF / Revenue | — | -5.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-5.8M | ||
| Q3 25 | $-4.3M | $-968.0K | ||
| Q2 25 | $-31.4M | $-4.0M | ||
| Q1 25 | $-22.6M | $-23.1M | ||
| Q4 24 | $-35.0M | $6.8M | ||
| Q3 24 | $-35.3M | $1.1M | ||
| Q2 24 | $-7.2M | $-8.9M | ||
| Q1 24 | $53.8M | $-16.8M |
| Q4 25 | — | $-7.8M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-7.0M | ||
| Q1 25 | — | $-25.3M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | $-35.5M | $101.0K | ||
| Q2 24 | $-7.3M | $-11.0M | ||
| Q1 24 | $53.8M | $-19.9M |
| Q4 25 | — | -5.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | — | -6.6% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | -68.7% | 0.1% | ||
| Q2 24 | -9.9% | -9.2% | ||
| Q1 24 | 39.0% | -16.5% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | 0.1% | 1.7% | ||
| Q1 24 | 0.1% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
